Skip to Content

Avibactam / ceftazidime Pregnancy and Breastfeeding Warnings

Avibactam / ceftazidime is also known as: Avycaz

Avibactam / ceftazidime Pregnancy Warnings

This drug should be used during pregnancy only if clearly needed. US FDA pregnancy category: B

Animal studies have failed to reveal evidence of fetal harm with ceftazidime. Animal studies have failed to reveal evidence of teratogenicity or embryofetal toxicity with avibactam at doses up to 11 and 2 times the human exposure (based on AUC) in rats and rabbits, respectively; increased post-implantation loss, reduced fetal weights, delayed ossification of several bones, and other anomalies were seen with higher doses in rabbits. There are no controlled data in human pregnancy. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Avibactam / ceftazidime Breastfeeding Warnings

Use of ceftazidime (alone) during breastfeeding is considered acceptable. According to limited data, single maternal doses (up to 2 g) produce low levels in milk that are not expected to cause harmful effects in the nursing infant. Ceftazidime (2 g IV every 8 hours for 5 days) was used in 11 women. The trough milk levels averaged 3.8, 5.2, and 4.5 mg/L before the next dose, 1 hour after the dose, and 3 hours after the dose, respectively; not statistically significant. Drug milk levels averaged 3.9 mg/L for samples before the 7th dose and 4.9 mg/L in samples after the 7th dose; not statistically significant.

Caution is recommended. Excreted into human milk: Unknown (avibactam); Yes (ceftazidime [low levels]) Excreted into animal milk: Yes (avibactam [dose-dependent]) Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Avycaz (avibactam-cefTAZidime)." Forest Pharmaceuticals, St. Louis, MO.

References for breastfeeding information

  1. "Product Information. Avycaz (avibactam-cefTAZidime)." Forest Pharmaceuticals, St. Louis, MO.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.